军人边走边吮她的花蒂,国内精品久久人妻无码hd,av无码精品一区二区三区,初学生毛没长齐偷吃禁果

訂購(gòu)信息
上海拜力生物科技公司
Tel:400-968-7988    021-33779008
TH-302,Hypoxia-activatedPro-drug
品牌:Xcessbio
貨號(hào):M60089-5s
規(guī)格:5 mg solid
貨期:
應(yīng)用: 點(diǎn)擊這里給我發(fā)消息  咨詢客服

TH-302,Hypoxia-activatedPro-drug

商品詳情 參考文獻(xiàn) 相關(guān)資料
Product Information
Molecular Weight: 449.04
Formula: C9H16FBr2N6O4P
Purity: ≥ 98%
CAS#: 918633-87-1
Solubility: DMSO up to 50 mM
Chemical Name: (1-methyl-2-nitro-1H-imidazol-5-yl)methyl N,N-bis(2-bromoethyl)phosphordiamidate
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

TH-302 is a highly potent and selective hypoxia-activated pro-drug targeting hypoxic regions of solid tumors with an IC50 of 19 nM. It is stable to liver microsomes. However, under hypoxic conditions, it is selectively and irreversibly converted to its active phosphoramidate-based, DNA-crosslinking, bis-alkylator. TH-302 inhibits H460 cells and HT29 cells with IC90 of 0.1 μM and 0.2 μM, respectively. It shows much enhanced potency in H460 spheroids compared to H460 monolayer cells under normoxia. TH-302 exhibits potent cytotoxicity to both human and murine MM cells with hypoxic selectivity and dose dependency, and induces G0/G1 cell-cycle arrest under hypoxic conditions. It inhibits primary tumor growth in multiple xenograft models. TH-302 is currently in a phase II clinical trial for the treatment of soft tissue sarcoma.


How to Use:

  • In vitro: TH-302 was used at 1 μM concentration in vitro and cellular assays.
  • In vivo: TH-302 was intraperitoneally (IP) dosed to mice at 50 mg/kg once per day to inhibit tumor growth.


Reference:

  1. 1. Duan JX, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. (2008) J Med Chem. 51(8):2412-20.
  2. 2. Hu J, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. (2010) Blood. 116(9):1524-7.
  3. 3. Weiss GJ, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. (2011) Clin Cancer Res. 17(9):2997-3004.
  4. 4. Meng F, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. (2012) Mol Cancer Ther. 11(3):740-51.
  5. 5. Sun JD, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. (2012) Clin Cancer Res. 18(3):758-70.
  6. 6. Moyer MW. Targeting hypoxia brings breath of fresh air to cancer therapy. (2012) Nat Med. 18(5):636-7.



Products are for research use only. Not for human use.

熱銷產(chǎn)品
熱銷產(chǎn)品排行榜
  • 關(guān)于我們
  • 購(gòu)物流程
  • 支付方式
  • 配送方式

請(qǐng)打開(kāi)QQ掃碼聯(lián)系
Copyright@ 2003-2024  進(jìn)口試劑采購(gòu)網(wǎng)版權(quán)所有     

BIOLEAF熱搜   BIOLEAF試劑盒   BIOLEAF ELISA   BIOLEAF試劑   BIOLEAF品牌   BIOLEAF抗體   BIOLEAF耗材   BIOLEAF小儀器

sitemap   細(xì)胞庫(kù)查詢   危險(xiǎn)品圖標(biāo)

本公司網(wǎng)站所展示銷售的產(chǎn)品僅供科研!

         滬ICP備08023583號(hào)-6     
產(chǎn)品咨詢
QQ掃碼溝通
在線客服
服務(wù)電話
400-968-7988
掃碼關(guān)注
微信公眾號(hào)二維碼

滬公網(wǎng)安備 31011202007338號(hào)